ERBB2 and cancer: Specifically, we evaluated the ability of different machine and deep learning models to predict (1) benign vs. malignant lesions; (2) low-grade (G1 + G2) vs. high-grade (G3) tumors; and (3) HER2-positive vs. HER2-negative cancers.